Holen Sie sich die Stockscreener-App
7.865
4.20%
-0.345
Schlusskurs vom Vortag:
$8.21
Offen:
$8.21
24-Stunden-Volumen:
13,479
Relative Volume:
0.04
Marktkapitalisierung:
$6.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.0296
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
+3.90%
1M Leistung:
+14.48%
6M Leistung:
-92.35%
1J Leistung:
-99.16%
1-Tages-Spanne:
$7.809
$8.40
1-Wochen-Bereich:
$7.32
$8.48
52-Wochen-Spanne:
$6.1478
$942.48
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Vergleichen Sie RNAZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
7.906 | 6.30M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.56 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.85 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.56 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
559.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.85 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
TransCode Therapeutics (NASDAQ:RNAZ) Trading 4.7% Higher – Here’s Why - Defense World
TransCode Therapeutics Announces 2025 Annual Meeting Date - TipRanks
(RNAZ) Investment Analysis - news.stocktradersdaily.com
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
(RNAZ) On The My Stocks Page - news.stocktradersdaily.com
Transcode Therapeutics Appoints Dr. Phillip D. Zamore To Science Advisory Board - marketscreener.com
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - citybiz
TransCode Therapeutics appoints RNA expert to advisory board - Investing.com
TransCode Therapeutics appoints RNA expert to advisory board By Investing.com - Investing.com Nigeria
Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan
TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen - Defense World
Certain Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
When (RNAZ) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail
Transcode Therapeutics (RNAZ) Trading Halted Pending News Announ - GuruFocus
Transcode Therapeutics (RNAZ) Trading Halted Pending News Announcement | RNAZ Stock News - GuruFocus
TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Wednesday - Defense World
Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday - Defense World
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
(RNAZ) Investment Report - news.stocktradersdaily.com
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - Stock Titan
TransCode Therapeutics Faces Nasdaq Delisting Risk - TipRanks
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares - Stock Titan
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga
Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday - Benzinga
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - citybiz
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com India
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split - GuruFocus
Offerings News Live Feed - Stock Titan
Transcode Therapeutics Announces 1-For-28 Reverse Stock Split - marketscreener.com
TransCode Therapeutics (RNAZ) Announces 1-for-28 Reverse Stock Split - GuruFocus
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules - Investing.com
TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall - MSN
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split | RNAZ Stock News - GuruFocus
TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split - marketscreener.com
TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing - Stock Titan
TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside - MSN
For Dropbox Inc [DBX], Analyst sees a drop to $30. What next? - dbtnews.com
Direct Digital Holdings Inc [DRCT] is -44.37% lower this YTD. Is it still time to buy? - dbtnews.com
CN Energy Group Inc [CNEY] Is Currently 9.75 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Wall Street Analyst Upgrade Rush Street Interactive Inc [RSI]. What else is Wall St. saying - dbtnews.com
why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com
Glaukos Corporation [GKOS] Revenue clocked in at $383.48 million, down -44.28% YTD: What’s Next? - dbtnews.com
Republic Digital Acquisition Company [RDAGU] Stock trading around $10.15 per share: What’s Next? - dbtnews.com
Venture Global Inc [VG] stock Initiated by UBS analyst, price target now $14 - dbtnews.com
Hayward Holdings Inc [HAYW] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Market cap of Solaris Energy Infrastructure Inc [SEI] reaches 1.55B – now what? - dbtnews.com
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):